| Application of artificial intelligence using a convolutional neural network for detecting gastric cancer in endoscopic images |
83 |
| Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007) |
61 |
| Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study |
49 |
| Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection |
43 |
| A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607) |
33 |
| Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer |
30 |
| Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis |
29 |
| A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A) |
24 |
| Higher incidence of pancreatic fistula in laparoscopic gastrectomy. Real-world evidence from a nationwide prospective cohort study |
19 |
| Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma |
19 |
| A feasibility study of laparoscopic total gastrectomy for clinical stage I gastric cancer: a prospective multi-center phase II clinical trial, KLASS 03 |
19 |
| Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401 |
19 |
| EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions |
18 |
| The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis |
18 |
| A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538- ATTRACTION-2) |
18 |
| Clinical advantages of robotic gastrectomy for clinical stage I/II gastric cancer: a multi-institutional prospective single-arm study |
18 |
| Introducing laparoscopic total gastrectomy for gastric cancer in general practice: a retrospective cohort study based on a nationwide registry database in Japan |
17 |
| Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis |
17 |
| CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial |
17 |
| Long-term oncologic outcomes of robotic gastrectomy for gastric cancer compared with laparoscopic gastrectomy |
16 |
| Enhanced recovery versus conventional care in gastric cancer surgery: a meta-analysis of randomized and non-randomized controlled trials |
16 |
| Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial |
16 |
| Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer |
15 |
| Long-term outcomes of endoscopic submucosal dissection versus surgery in early gastric cancer meeting expanded indication including undifferentiated-type tumors: a criteria-based analysis |
15 |
| Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach? |
14 |
| The long-term survival of stage IV gastric cancer patients with conversion therapy |
14 |
| MicroRNA-1 acts as a tumor suppressor microRNA by inhibiting angiogenesis-related growth factors in human gastric cancer |
14 |
| Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma |
14 |
| Prognostic importance of the preoperative modified systemic inflammation score for patients with gastric cancer |
14 |
| Downregulation of miR-142-5p promotes tumor metastasis through directly regulating CYR61 expression in gastric cancer |
13 |
| International consensus on a complications list after gastrectomy for cancer |
13 |
| Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer |
13 |
| Total vs proximal gastrectomy for adenocarcinoma of the upper third of the stomach: a propensity-score-matched analysis of a multicenter western experience (On behalf of the Italian Research Group for Gastric Cancer-GIRCG) |
12 |
| Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset |
12 |
| Robotic-assisted gastrectomy for gastric cancer: a European perspective |
12 |
| The predictive value of the preoperative C-reactive protein-albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data |
12 |
| Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer |
12 |
| The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials |
12 |
| Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications |
11 |
| Long-term outcomes of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG0703) |
11 |
| PODXL, negatively regulated by KLF promotes the EMT and metastasis and serves as a novel prognostic indicator of gastric cancer |
11 |
| Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment |
11 |
| HOTAIR induces the ubiquitination of Runx3 by interacting with Mex3b and enhances the invasion of gastric cancer cells |
11 |
| Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) |
11 |
| Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501) |
10 |
| Genome-wide long non-coding RNAs identified a panel of novel plasma biomarkers for gastric cancer diagnosis |
10 |
| Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer |
10 |
| The comprehensive complication index (CCI) is a more sensitive complication index than the conventional Clavien-Dindo classification in radical gastric cancer surgery |
10 |
| Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer |
10 |
| Validation of the prognostic impact of the new tumor-node-metastasis clinical staging in patients with gastric cancer |
10 |
